Company contacts
Exact Sciences Laboratories
Investor Relations
Please contact our Investor Relations team for questions about current and potential investing opportunities.
Media Relations
Please contact our Media Relations team for press releases, related assets, and more.
Medical Affairs
If you’re a healthcare provider, please reach out to ask questions or make comments about the Cologuard® test.
Card List, Header + Text cards, Inverse (dark mode) with Caption
Most major insurance carriers cover the Breast Recurrence Score Test
Tag
Including Medicare, Medicaid, Aetna, Anthem, Cigna, Humana, and UnitedHealthcare.
90% of Breast Recurrence Score Test patients paid less than $100
Tag
86% of patients paid nothing at all.
*The numbers cited are based on historical patient billing data from 1/2/2023 to 12/29/2023. Rates of coverage vary by state and region. Exceptions for coverage may apply. Exact Sciences strongly encourages you to contact your insurer with questions about Oncotype DX Breast Recurrence Score test coverage.
Card List, Header + Text cards, Default with Caption
Most major insurance carriers cover the Breast Recurrence Score Test
Tag
Including Medicare, Medicaid, Aetna, Anthem, Cigna, Humana, and UnitedHealthcare.
90% of Breast Recurrence Score Test patients paid less than $100
Tag
86% of patients paid nothing at all.
*The numbers cited are based on historical patient billing data from 1/2/2023 to 12/29/2023. Rates of coverage vary by state and region. Exceptions for coverage may apply. Exact Sciences strongly encourages you to contact your insurer with questions about Oncotype DX Breast Recurrence Score test coverage.
Card List, Header + Text cards with Image, Header option - H4
The risk of your cancer recurring
How likely you are to benefit from chemotherapy — or from hormone therapy alone
How likely your tumor is to spread
Card List, Header + Text cards with Image, Header option - H5
The risk of your cancer recurring
How likely you are to benefit from chemotherapy — or from hormone therapy alone
How likely your tumor is to spread
Card List, Header + Text cards with Image, Header option - H6
The risk of your cancer recurring
How likely you are to benefit from chemotherapy — or from hormone therapy alone
How likely your tumor is to spread
Card List, Header + Text cards with Image, Header option - Display 1
Title 1 Display 1
Title 2 Display 1
Title 3 Display 1
Card List, Header + Text cards with Image, Alphanumeric Indicator, and Body content
Reduced over-treatment for 600,000+ women tested
Out of 1.5 million women tested, 1.3 million of them had a low risk of recurrence and wouldn’t benefit from chemotherapy
Card List, Header + Text cards with/without Images, Header option - H4, Tertiary Links
The risk of your cancer recurring
How likely you are to benefit from chemotherapy — or from hormone therapy alone
How likely your tumor is to spread
Card List, Header + Text cards with/without Images, Header option - H4, Tertiary Links, Dark Theme
The risk of your cancer recurring
How likely you are to benefit from chemotherapy — or from hormone therapy alone
How likely your tumor is to spread
Card List, Header + Text cards without Images, Header option - H4, Tertiary Links
Card List, Header + Text cards without Images, Header option - H4, Tertiary Links Gray
The risk of your cancer recurring
How likely you are to benefit from chemotherapy — or from hormone therapy alone
How likely your tumor is to spread